Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7941523 | 1.00 | KMT2A (0.46) | KMT2ATRIM24TRIM33ALDH1A1CA1 | |
| SCHEMBL22236194 | 0.91 | TRIM24 (0.53) | KMT2ATRIM24TRIM33ALDH1A1CA1 | |
| SCHEMBL12650057 | 0.86 | TRIM24 (0.55) | KMT2ATRIM24TRIM33ALDH1A1CA1 | |
| SCHEMBL7940476 | 0.84 | TRIM24 (0.52) | KMT2ATRIM24TRIM33ALDH1A1CA1 | |
| SCHEMBL12844398 | 0.84 | KMT2A (0.41) | KMT2ATRIM24TRIM33ALDH1A1CA1 | |
| SCHEMBL7145748 | 0.83 | TRIM24 (0.34) | KMT2ATRIM24TRIM33ALDH1A1CA1 | |
| SCHEMBL22235985 | 0.81 | KMT2A (0.38) | KMT2ATRIM24TRIM33ALDH1A1CA1 | |
| SCHEMBL14551906 | 0.80 | — | — | |
| SCHEMBL7714747 | 0.80 | — | — | |
| SCHEMBL1771596 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362023-B1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | GIVAUDAN SA (CH) | 2009-04-15 | — | — | EP | claimed |
| US-6951964-B2 | Method for producing macrocyclic ketones | GIVAUDAN SA (CH) | 2005-10-04 | — | — | US | claimed |
| US-20040082816-A1 | Method for producting macrocyclic ketones | GIVAUDAN SA (CH) | 2004-04-29 | — | — | US | claimed |
| EP-1236707-A1 | Process for the preparation of macrocyclic ketones | Givaudan SA (CH) | 2002-09-04 | — | — | EP | claimed |
| EP-1362023-B1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | GIVAUDAN SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-6951964-B2 | Method for producing macrocyclic ketones | GIVAUDAN SA (CH) | 2005-10-04 | — | — | US | disclosed |
| US-20040082816-A1 | Method for producting macrocyclic ketones | GIVAUDAN SA (CH) | 2004-04-29 | — | — | US | disclosed |
| EP-1362023-A1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | Givaudan SA (CH) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068372-A1 | METHOD FOR PRODUCING MACROCYCLIC KETONES | GIVAUDAN SA (CH) | 2002-09-06 | — | — | WO | disclosed |
| EP-1236707-A1 | Process for the preparation of macrocyclic ketones | Givaudan SA (CH) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082816-A1 | Method for producting macrocyclic ketones | ADH1C, ADH1A, AKR1C3 | KMT2A 3232/4885TRIM24 3080/4885TRIM33 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.